A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner

There is an urgent need for better therapeutic options for advanced melanoma patients, particularly those without the BRAF(V600E/K) mutation. In melanoma cells, loss of TRIM16 expression is a marker of cell migration and metastasis, while the BRAF inhibitor, vemurafenib, induces melanoma cell growth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Sutton, Selina K., Carter, Daniel R., Kim, Patrick, Tan, Owen, Arndt, Greg M., Zhang, Xu Dong, Baell, Jonathan, Noll, Benjamin D., Wang, Shudong, Kumar, Naresh, McArthur, Grant A., Cheung, Belamy B., Marshall, Glenn M.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5239542/
https://ncbi.nlm.nih.gov/pubmed/27447557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10700
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados